El interés en corto de LifeStance Health Gr da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de LifeStance Health Gr. Los datos de interés en corto se actualizan cada dos semanas.

LifeStance Health Gr (NASDAQ:LFST) Bolsa, Informe de interés en corto

LifeStance Health Gr

LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.

LifeStance Health Group

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Group Inc

Pagaya Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.92, with a high estimate of $36.00 and a low estimate of $11.00. Observing a downward trend, the current average is 12.42% lower than the prior average price target of $26.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1742220069_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Pagaya Techs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Peter Christiansen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pagaya Techs. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pagaya Techs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Pagaya Techs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pagaya Techs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PGY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pagaya Techs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Pagaya Techs's Background</h2>
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, big data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
<h3>Financial Insights: Pagaya Techs</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Pagaya Techs's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 31.0%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Pagaya Techs's net margin is impressive, surpassing industry averages. With a net margin of -86.31%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Pagaya Techs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -60.33%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Pagaya Techs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -17.88%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.09, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Pagaya Techs's Future

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $220.31, along with a high estimate of $248.00 and a low estimate of $195.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.16%. 
<img src="https://www.benzinga.com/files/images/story/2025/1742220057_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive American Tower is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$248.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ari Klein</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Simon Flannery</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$213.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$225.00</td>
<td>-</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$220.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$204.00</td>
<td>$221.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to American Tower. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of American Tower compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of American Tower's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of American Tower's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on American Tower analyst ratings.</a>
<h2>Discovering American Tower: A Closer Look</h2>
American Tower owns and operates more than 220,000 cell towers throughout the US, Asia, Latin America, Europe, and Africa. It also owns and/or operates 28 data centers in 10 US markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the US, which accounted for almost half of the company's total revenue in 2023. Outside the US, American Tower operates over 75,000 towers in India, almost 50,000 towers in Latin America (dominated by Brazil), 30,000 towers in Europe, and nearly 25,000 towers in Africa. American Tower operates as a REIT.
<h3>Understanding the Numbers: American Tower's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: American Tower's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.73%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: American Tower's net margin is impressive, surpassing industry averages. With a net margin of 48.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): American Tower's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 35.01% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): American Tower's ROA stands out, surpassing industry averages. With an impressive ROA of 1.98%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: American Tower's debt-to-equity ratio surpasses industry norms, standing at 13.0. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About American Tower Stock

B. Riley Securities analyst Hal Goetsch reiterates Pagaya Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) with a Buy and maintains $36 price target.

News

Price Target

Reiteration

B. Riley Securities Reiterates Buy on Pagaya Techs, Maintains $36 Price Target

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $42.0, a high estimate of $47.00, and a low estimate of $39.00. This current average reflects an increase of 24.44% from the previous average price target of $33.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1742220047_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Chewy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Lauren Schenk</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Chewy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Chewy compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Chewy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Chewy's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CHWY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chewy analyst ratings.</a>
<h2>Delving into Chewy's Background</h2>
Chewy is the largest e-commerce petcare retailer in the US, generating $11.2 billion in fiscal 2023 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
<h3>Chewy's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Chewy showcased positive performance, achieving a revenue growth rate of 4.8% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Chewy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.11%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Chewy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 2.29, Chewy faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHWY

A Glimpse Into The Expert Outlook On Chewy Through 4 Analysts

Macro Economic Events

Econ #s

Economics

USA Retail Inventories Ex Auto For January 0.5% Vs 0.4% Est.; -0.1% Prior

4 analysts have expressed a variety of opinions on FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.25, with a high estimate of $22.00 and a low estimate of $19.00. This current average has increased by 2.41% from the previous average price target of $20.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1742220034_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive FS KKR Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to FS KKR Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FS KKR Capital compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of FS KKR Capital's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FS KKR Capital analyst ratings.</a>
<h2>About FS KKR Capital</h2>
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
<h3>Key Indicators: FS KKR Capital's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining FS KKR Capital's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 42.64% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: FS KKR Capital's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 79.89% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): FS KKR Capital's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.21%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.0%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: FS KKR Capital's debt-to-equity ratio is below the industry average at 1.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into FS KKR Capital Stock: Analyst Perspectives (4 Ratings)

Even the <a href="https://www.benzinga.com/news/24/12/42638666/rockefeller-rich-elon-musks-wealth-hits-rockefeller-rich-levels-equivalent-to-a-1-6-share-of-the-u-s-gdp">world's richest man</a> isn't immune to financial headaches, and apparently, neither is his family. Elon Musk, whose net worth still hovers around $330 billion despite record losses recently, isn't the only one navigating the highs and lows of wealth. His sister, Tosca Musk, says having the last name "Musk" comes with a price—literally.
Tosca, a filmmaker and the founder of Passionflix, revealed that when scouting locations for a production, she encountered a steep markup simply because of her famous last name.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>
"The location was going to cost $5,000 a day," Tosca told the <a href="https://www.dailymail.co.uk/femail/article-12208147/Tosca-Musk-reveals-assumes-Elon-pays-picked-sperm-donor.html">Daily Mail in 2023</a>. "But when they heard my name and assumed we were rich, they decided to charge us $25,000."
That's a 400% increase—simply for being related to Elon Musk.
<h2 class="wp-block-heading">The Double-Edged Sword of the Musk Name</h2>
Tosca admitted that the Musk name is both a "blessing and a curse." While it undoubtedly opens doors, it also comes with assumptions—many of which aren't true.
"Everyone assumes my eldest brother pays for everything, but he does not," she said, explaining that while she and Elon share a strong sibling bond, he's not bankrolling her ventures.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
"It's a double-edged sword for me to say whether my brother has helped in any way. If I say no, then people will say he does not support me at all, and if I say yes, they'll think he paid for everything."
She founded Passionflix in 2017 to adapt romance novels into films, after struggling to get traditional networks or studios interested in the genre. Despite being part of one of the world's most well-known families, funding the company wasn't easy.
<h2 class="wp-block-heading">A Family That Wasn't Born Rich</h2>
The Musk siblings—Elon, Tosca, and Kimbal—didn't grow up in the kind of wealth many assume. Their mother, Maye Musk, worked as a model while raising them, often bringing them to her jobs because <a href="https://www.benzinga.com/personal-finance/25/01/42771425/elon-musks-mom-says-struggling-parents-can-skip-the-movies-or-dining-out-just-spend-time-with-the-most-wonderful-gifts-you-can-ever-have">she couldn't afford childcare</a>.
"As children, we were given a lot of freedom, but with it came responsibility," Tosca recalled. "You had to take care of yourself, learn how to cook and clean, and be supportive of the people who were doing everything they could to support you in life."
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
That mindset carried over into her own parenting. When faced with public scrutiny, she reassured her children by reminding them that public perception doesn't define them.
"I told my kids, ‘Do you know us and do you think that's who we are? If you know what the truth is about our family, don't believe what others say.'"
<h2 class="wp-block-heading">Ambitions Beyond the Musk Name</h2>
Despite the challenges of being a Musk, Tosca has no desire to change her last name.
"It's mostly a blessing, and I would never be tempted to change it," she said. "Even if it means getting upcharged."
As for her future goals? "I'd like our films to win some Emmys, an Oscar, maybe a BAFTA—all the awards—so that people will pay attention to romance."
With a name like Musk, <a href="https://www.benzinga.com/startups/25/01/43101102/elon-musk-the-richest-man-in-the-world-is-estimated-to-earn-over-23-million-every-single-hour-of-the-day-heres-how-hes-spending-it">people are definitely paying attention</a>.
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

Elon Musk's Little Sister Says Her Last Name Is a 'Blessing and a Curse'—Prices Soar When People Realize Her Brother Is the World's Richest Man

Analysts' ratings for Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $13.67, a high estimate of $17.00, and a low estimate of $10.00. Witnessing a positive shift, the current average has risen by 3.17% from the previous average price target of $13.25.
<img src="https://www.benzinga.com/files/images/story/2025/1742220026_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Rivian Automotive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Rivian Automotive. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rivian Automotive compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Rivian Automotive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Rivian Automotive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RIVN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rivian Automotive analyst ratings.</a>
<h2>Discovering Rivian Automotive: A Closer Look</h2>
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues primarily from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.
<h3>Understanding the Numbers: Rivian Automotive's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Rivian Automotive showcased positive performance, achieving a revenue growth rate of 31.86% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -42.91%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Rivian Automotive's ROE excels beyond industry benchmarks, reaching -11.95%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Rivian Automotive's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.01%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.87.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RIVN

What 12 Analyst Ratings Have To Say About Rivian Automotive

During the last three months, 14 analysts shared their evaluations of Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $40.43, a high estimate of $45.00, and a low estimate of $32.00. This current average has increased by 8.01% from the previous average price target of $37.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1742220017_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Range Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bertrand Hodee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Umang Choudhary</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Cameron Bean</td>
<td>Scotiabank</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bertrand Hodee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Range Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Range Resources compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Range Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Range Resources's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Range Resources analyst ratings.</a>
<h2>Delving into Range Resources's Background</h2>
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
<h3>A Deep Dive into Range Resources's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Range Resources showcased positive performance, achieving a revenue growth rate of 4.5% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Range Resources's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 14.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Range Resources's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.42%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Range Resources's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.29%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.46.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 14 Analysts Discuss Range Resources Stock

USA Business Inventories (MoM) For January 0.3% Vs 0.3% Est.; -0.2% Prior

MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) has outperformed the market over the past 5 years by 71.4% on an annualized basis producing an average annual return of 91.27%. Currently, MARA Holdings has a market capitalization of $4.49 billion. 
Buying $100 In MARA: If an investor had bought $100 of MARA stock 5 years ago, it would be worth $2,753.54 today based on a price of $13.22 for MARA at the time of writing.
<h3>MARA Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742220010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MARA

Here's How Much $100 Invested In MARA Holdings 5 Years Ago Would Be Worth Today

NAHB Housing Market Index For March 39 Vs 42 Est.; 42 Prior

Canadian Pacific Kansas City (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CP#TSX">CP</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) (CPKC) today said that United Steelworkers (USW), representing approximately 600 clerical and intermodal employees in Canada, has ratified a new&nbsp;four-year collective agreement.

TSX:CP

Canadian Pacific Kansas City Says United Steelworkers, Representing ~600 Clerical And Intermodal Employees In Canada, Has Ratified A New 4-Year Collective Agreement

Citizens Capital Markets analyst Devin Ryan reiterates Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Market Outperform and maintains $94 price target.

SCHW

Citizens Capital Markets Reiterates Market Outperform on Charles Schwab, Maintains $94 Price Target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

Regencell Bioscience Shares Halted On Circuit Breaker To The Upside, Stock Now Up 34.9%

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $10 price target.

CRVO

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

Guidance

SKYX

SKYX Platforms Sees Prelim. Q4 Revenue $23.7M Vs $24.3M Est.

Citizens Capital Markets analyst Aaron Hecht reiterates Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) with a Market Outperform and maintains $20 price target.

REFI

Citizens Capital Markets Reiterates Market Outperform on Chicago Atlantic Real, Maintains $20 Price Target

On Monday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)&nbsp;released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">hidradenitis suppurativa (HS)</a>.
Hidradenitis suppurativa (HS), also known as acne inversa, is&nbsp;a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead to abscesses and scarring.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44245346/eli-lilly-incyte-partnered-fda-approved-drug-shows-encouraging-efficacy-in-adolescent-patients-with-patchy-hair-loss" rel="noreferrer noopener">Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss</a>
STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg).
A significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44352766/incyte-announces-positive-topline-results-from-two-phase-3-clinical-trials-of-povorcitinib-in-pati" rel="noreferrer noopener">draining tunnel count</a>.
The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was:
<ul>
<li>STOP-HS1: 45 mg: 40.2% vs. 29.7% [P=0.024]; 75 mg: 40.6% vs 29.7% [P=0.022].</li>
<li>STOP-HS2: 45 mg: 42.3% vs. 28.6% [P=0.004]; 75 mg: 42.3% vs. 28.6% [P=0.003].</li>
</ul>
Within a predefined subgroup of patients previously exposed to biologics, povorcitinib demonstrated greater differential efficacy (HiSCR50) when compared to placebo:
<ul>
<li>STOP-HS1: 45 mg: 34.2% vs. 21.9% [P=0.096]; 75 mg: 37.8% vs. 21.9% [P=0.037].</li>
<li>STOP-HS2: 45 mg: 45.0% vs. 19.5% [P=0.001]; 75 mg: 40.0% vs. 19.5% [P=0.005].</li>
</ul>
In addition, at Week 12, patients treated with povorcitinib achieved deep levels of clinical response with a greater proportion achieving HiSCR75, reduction in flares,&nbsp;&gt;3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30.
Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.
The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated.
Last week, Incyte revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis, a chronic skin condition characterized by <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44229321/incyte-releases-mixed-data-from-late-stage-opzelura-studies-in-skin-disease-characterized-by-itchy-firm-lumps" rel="noreferrer noopener">very itchy firm lumps</a>.
Price Action: INCY stock is down 11.90% at $59.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

INCY

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

Earnings

Press Releases

LifeStance Reports Second Quarter 2024 Results

Legal

Bragar Eagel & Squire, P.C. Is Investigating LifeStance and Customers Bancorp and Encourages Investors to Contact the Firm

LifeStance to Present at the 22nd Annual Morgan Stanley Healthcare Conference

LifeStance Survey Finds 79% of Americans Are Experiencing Anxiety Over the 2024 U.S. Presidential Election

LifeStance to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024

LifeStance Reports Third Quarter 2024 Results

Financing

Zarminali Health Launches with $40M in Seed Funding to Transform Pediatric Care through Nationwide, Multi-specialty Practice Group

LifeStance to Host Fourth Quarter and Full Year 2024 Earnings Conference Call on February 27, 2025

LifeStance Reports Fourth Quarter and Full Year 2024 Results

LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman

CUBI

LFST

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

LifeStance Health Gr

Interés en corto

LifeStance Health Gr (NASDAQ:LFST) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL